Inhibitors of FAK that target the ATP-binding pocket of the kinase domain have been largely unsuccessful10,11, displaying micromolar anti-proliferative effects and no apoptotic effects in cancer cells despite reported nanomolar biochemical potencies for the FAK enzyme12,13. Here, PTK2 is linked to cancer.